{
Bristol-Myers Squibb Company

Companies

}
001122334455554433221100
001122334455554433221100

pharmaceutical industry struggles to improve access to medicine in low-income countries

Pharmaceutical companies are increasingly focusing on access to medicines in low-income countries, with Novartis leading the way by integrating access plans into 96% of its late-stage drug projects. However, many companies still prioritize the US market, resulting in limited availability of essential medicines globally. Roche aims to double patient treatment numbers in low-income regions by 2026, yet significant gaps in transparency and patient reach persist across the industry.
SWI swissinfo.ch
Bristol-Myers Squibb Company GSK plc Hoffmann-La Roche AG AbbVie Inc. Sanofi Novo Nordisk A/S Novartis AG Johnson & Johnson Pfizer Inc. GBR CHE NLD Jayasree Iyer Sabastine Wakdok Show more
Healthcare, Market Report
14:30 19.11.2024

global hashimoto thyroiditis market projected to reach 12.6 billion by 2033

The global Hashimoto"s thyroiditis market is projected to grow from $8.3 billion in 2023 to $12.6 billion by 2033, with a CAGR of 4.26%. North America is expected to dominate the market, while Asia-Pacific will experience the fastest growth due to rising healthcare awareness and improved infrastructure. The tablet segment will hold the largest market share, driven by convenience and patient compliance.
Spherical Insights
United States Dollar Amgen Inc. Merck & Co., Inc. Novartis AG Sanofi Mylan N.V. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Company Takeda Pharmaceuticals Limited Company Bayer AG Pfizer Inc. Roche Holding AG AbbVie Inc. AstraZeneca PLC Eli Lilly and Company Glaxosmithkline plc ARG GBR FRA ITA KOR ZAF MEX USA BRA ESP SAU CAN QAT ARE JPN AUS DEU CHN RUS IND Pfizer Inc. AbbVie Inc. Mylan N.V. Inc. Merck & Co GlaxoSmithKline plc Show more
Healthcare, Market Report
04:38 19.11.2024

ew immunosuppressive drug launched enhancing access for kidney transplant patients

A new generic immunosuppressive drug has been launched, enhancing access for kidney transplant patients. The global solid organ transplantation market is projected to grow, driven by innovations in transplantation methods, increased organ donation awareness, and tailored immunosuppressive treatments. North America is expected to dominate the market, while Asia-Pacific is poised for the fastest growth due to expanding healthcare infrastructure and rising public awareness.
Spherical Insights
United States Dollar GSK plc Bristol-Myers Squibb Company Johnsons and Johnsons Services Inc. Merck & Co., Inc. Leo Pharma A/S Mylan N.V. Ascendis Pharma A/S Teva Pharmaceutical Industries Ltd. Celltrion Inc. Hoffman-La Roche Ltd. ESP IND QAT GBR JPN KOR AUS ARE CHN DEU USA BRA RUS MEX CAN ARG FRA ITA SAU ZAF Show more
Healthcare, Market Report
04:04 19.11.2024

Merck"s under-the-skin Keytruda shows promise in Phase 3 trial

Merck"s experimental under-the-skin injection of Keytruda demonstrated comparable characteristics to the intravenous version in a Phase 3 trial, prompting plans for discussions with regulators. With the IV formulation"s U.S. patent set to expire in 2028, Merck aims to sustain revenue from its leading cancer drug, which generated nearly $22 billion in sales in 2024. The subcutaneous version could offer greater convenience and is protected by new patents, but timely approval is crucial to fend off emerging biosimilar competition.
BioPharma Dive
United States Dollar Merck & Co., Inc. Celltrion Bristol-Myers Squibb Company Hoffmann-La Roche AG Amgen Inc. Samsung Bioepis Sandoz Group AG USA Show more
Healthcare, Market Report
01:00 19.11.2024

Cramer doubts RFK Jr. will disrupt drug and junk food industries

Jim Cramer expressed skepticism about the potential impact of Robert F. Kennedy Jr.'s nomination as head of the Department of Health and Human Services on the drug and junk food industries. Despite Kennedy's vaccine skepticism and opposition to processed foods, Cramer believes that government staff and lobbyists will resist significant changes, and that the industries are resilient. He cautioned investors against buying stocks in these sectors, particularly those related to vaccines, during a rate-cutting cycle.
CNBC
Moderna, Inc. General Mills, Inc. Bristol-Myers Squibb Company J.M. Smucker de Mexico SA de C.V Eli Lilly and Company PepsiCo, Inc. USA Jim Cramer Robert F. Kennedy Jr. Donald Trump Show more
Regulatory & Legal, Market Report
01:15 16.11.2024

Bristol-Myers Squibb focuses on diverse pharmaceutical treatments with strong US sales

Bristol-Myers Squibb Company focuses on developing, manufacturing, and marketing pharmaceutical products aimed at treating cancer, cardiovascular diseases, liver diseases, immune disorders, and psychiatric disorders. Notably, the United States represents 70.1% of the company's net sales. UBS maintains a neutral stance on the company.
MarketScreener
Bristol-Myers Squibb Company USA Show more
TradFi, Market Report
17:03 12.11.2024

global healthcare services market poised for significant growth through 2028

The global healthcare services market is projected to grow from $8,348.44 billion in 2023 to $8,963.64 billion in 2024, driven by advancements in medical technology, an aging population, and health insurance expansion. By 2028, it is expected to reach $10,908.99 billion, with key trends including telemedicine integration and patient-centered care. Shared medical appointments are gaining traction as a cost-effective model for managing chronic conditions, enhancing patient outcomes through collaborative care.
openPR.com
United States Dollar Community Health Systems, Inc. UnitedHealth Group Incorporated CVS Health Corporation Regeneron Pharmaceuticals, Inc. Cardinal Health, Inc. Fresenius Medical Care AG & Co. KGaA Centene Corporation Baxter International Inc. Mayo Clinic Agilent Technologies, Inc. Johnson & Johnson Pfizer Inc. Cleveland Clinic Global Solutions LLC McKesson Corporation Merck & Co., Inc. Abbott Laboratories Bristol-Myers Squibb Company Quest Diagnostics Incorporated HCA Healthcare, Inc. Gilead Sciences, Inc. Kaiser Permanente Group Trust Cigna Corporation Stryker Corporation Tenet Healthcare Corporation Danaher Corporation AbbVie Inc. Boston Scientific Corporation Molina Healthcare, Inc. Align Technology, Inc. AmerisourceBergen Corporation Laboratory Corporation OF America Holdings DaVita Inc. Eli Lilly and Company Humana Inc. West Pharmaceutical Services, Inc. Fresenius Medical Care AG & Co. KGaA Kaiser Permanente UnitedHealth Group Incorporated Tenet Healthcare HCA Healthcare Show more
Healthcare, Market Report
20:40 11.11.2024

teva reports strong generics demand raises 2024 revenue outlook

Teva Pharmaceuticals reported a 13% revenue increase in Q3, reaching $4.3 billion, driven by strong demand for its generics, particularly in the U.S. The company raised its full-year revenue guidance to $16.1-$16.5 billion, bolstered by successful products like Austedo and upcoming biosimilars, including Selarsdi and Simlandi. CEO Richard Francis emphasized a renewed focus on growth strategies to sustain this momentum.
BioSpace
United States Dollar Teva Pharmaceuticals Viatris Inc. AbbVie Inc. Bristol-Myers Squibb Company Novo Nordisk A/S Johnson & Johnson USA ISR Richard Francis AbbVie Johnson & Johnson Show more
Healthcare, Market Report
14:46 07.11.2024

global colorectal cancer therapeutics market projected to reach 19.90 billion by 2033

The colorectal cancer therapeutics market is projected to grow significantly, driven by increasing incidence rates, particularly in North America, where it holds the largest market share. Key developments include new product launches and strategic partnerships among major companies. The Asia-Pacific region is expected to experience the fastest growth due to rising awareness and screening initiatives.
Spherical Insights
United States Dollar Bayer AG Bristol-Myers Squibb Company Eli Lilly and Company Merck Sharp & Dohme Corp. Pfizer Inc. CHN FRA ESP BRA KOR IND ZAF ITA SAU ARG CAN USA RUS JPN MEX GBR DEU ARE AUS QAT American Cancer Society Takeda Reese Pharmaceutical Show more
Healthcare, Market Report
03:32 07.11.2024

nanotechnology revolutionizes cancer treatment with targeted drug delivery systems

Nanotechnology-based drug delivery systems are revolutionizing cancer treatment by enabling targeted drug delivery to tumors while minimizing harm to healthy tissues. The market is expected to grow rapidly, particularly in hospitals and clinics, driven by significant investments and advancements in North America and Asia-Pacific. Key players include major pharmaceutical companies, with ongoing innovations enhancing treatment efficacy and patient outcomes.
Spherical Insights
United States Dollar Celgene Company AstraZeneca PLC Amgen Inc. Johnson and Johnson Merck KGaA Pfizer Ltd Novartis International AG Bristol-Myers Squibb Company Teva Pharmaceutical Industries Limited CHN FRA ESP BRA KOR IND ZAF ITA SAU ARG CAN USA RUS JPN MEX GBR DEU ARE AUS QAT Nanobiotix SA Bristol-Myers Squibb Company Teva Pharmaceutical Industries Limited Johnson and Johnson Merck KGaA Show more
Healthcare, Market Report
22:36 06.11.2024
Trending
Subcategory
Corporate News Startups & Entrepreneurship Industry Trends Global Trade Developments Stock Market Updates Industry Mergers & Acquisitions Private Equity Deals Government Economic Policies Supply Chain Management Fintech Startups Venture Capital Investments Retail and Consumer Goods Inflation and Monetary Impact Workplace Trends Energy Sector Developments Finance Mergers & Acquisitions Central Bank Actions CEO Changes Emerging Startups Crypto Policies and Governance
Countries:
IND USA CHN ARE JPN SAU EGY SGP HKG TWN KOR IDN MYS THA BHR ISR PHL TGO AUS FRA
Companies:
Apple Inc. NIO Inc. Nikkei 225 Google Inc. Nintendo Co., Ltd. Grab2Go AS OLA ELECTRIC MOBILITY LTD Eurasia Groupe SA British International Investment plc XPeng Inc. Li Auto Inc. Morgan Stanley Taiwan Semiconductor Manufacturing Company Limited VFS Global AG LARGAN Precision Co.,Ltd S&P/ASX 200 HANG SENG BANK Delhivery Limited Ecom Express Ltd. Arazul Sequoia Capital FIM C Priv
Currencies:
United States Dollar Indian Rupee Euro Chinese Yuan Japanese Yen United Arab Emirates Dirham New Taiwan Dollar Indonesian Rupiah Saudi Riyal Offshore Chinese Yuan Hong Kong Dollar Malaysian Ringgit Filipino Peso West African CFA Franc South Korean Won Thai Baht Mexican Peso Croatian Kuna Bahraini Dinar Egyptian Pound
People:
Donald Trump Jerome Powell Joe Biden Nancy Wei Anwar Ibrahim James Smith George Davis Ariel Maislos Itamar Falcon Michael Ehrlich Youma Fall Christian Palouki Rahul Jain Ahmed Obaid Rodolphe Saadé Sahil Barua Pam Bondi Serene Sia Hana Raja Hsu Ken Ooi

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.